Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Trial details
- Registry ID
- NCT07326566
- Drugs studied
- silevertinib in combination with temozolomide, temozolomide (TMZ)
TrialRedline tracks 2 clinical trials sponsored by Black Diamond Therapeutics, Inc.: 1 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIINCT07326566 | silevertinib in combination with temozolomide, temozolomide (TMZ) | Recruiting | 2028-11Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsNCT05256290 | silevertinib monotherapy | Recruiting | 2028-03Estimated |
Names as written in the registry records.
NCT07326566 · Black Diamond Therapeutics, Inc.
Before: Not yet recruiting. After: Recruiting.